Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 2001–2050 of 75328
the Board appointed Coley O'Brien to succeed Mr. Hiller as Chief Human Resources Officer, effective May 18, 2026.
Mr. Herron has served as Chief Operating Officer of the Company since March 2023 and is retiring after over 15 years of dedicated service to the Company.
appointed Mike Hiller, Chief Talent Officer of the Company, as Chief Operating Officer-Designate effective May 18, 2026.
On May 15, 2026, the Board of Directors (the “Board”) of MediaAlpha, Inc. (the “Company”) appointed Lauren StClair as a member of the Board, filling the existing vacancy in Class I of the Board.
On May 12, 2026, Kah Loong Randy Yeo resigned from the Board of Directors of LQR House Inc. (the “ Company ”), effective immediately.
On May 12, 2026, Mr. Don Clegg, Senior Vice President of Worldwide Sales, informed Super Micro Computer, Inc. (the “Company”) that he will retire effective May 15, 2026.
Effective as of May 13, 2026, to fill vacancy in the composition of the Board of Directors (the “Board”), the Board of the Company appointed Peter O’Rourke to serve as a director
On May 14, 2026, the holders of Class B ordinary shares in McKinley Acquisition Corporation (the “Company”) appointed Joseph Shaposhnik as an additional independent director of the Company, and Mr. Shaposhnik consented to such appointment.
the Board decided to split the roles of Chief Executive Officer and President and has appointed P. Darryl Rensmon, the current EVP and Chief Operating Officer, as President effective June 1, 2026.
In anticipation of the future retirement of current President and Chief Executive Officer, Laura F. Clark, the Board decided to split the roles of Chief Executive Officer and President
On May 15, 2026, the Board of Directors (the “Board”) of T. Rowe Price Group, Inc. (the “Company”) approved the appointment of Eric L. Veiel to become the President, Co-Head of Global Investments and Chief Investment Officer of the Company, effective immediately.
On May 12, 2026, Jeremy Krol notified the Company of his voluntary resignation from the Board of Directors.
the Company and Mr. Krol agreed to the transition of Mr. Krol back into his role as Chief Operating Officer
On May 12, 2026, the Board of Directors appointed Dmitry Kroshka as Chief Executive Officer of the Company.
certified the election by its member, Mountain View Electric Association, Inc. (“MVEA”), of James Riggins to replace Rick Gordon, as the director representing MVEA on Tri-State’s Board of Directors effective as of June 4, 2026.
certified the election by its member, Mountain View Electric Association, Inc. (“MVEA”), of James Riggins to replace Rick Gordon, as the director representing MVEA on Tri-State’s Board of Directors effective as of June 4, 2026.
Brigette Roberts, M.D., was appointed to the Board as a Class III director.
Dr. Roberts was also appointed as the Chief of Corporate Affairs of the Company.
each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer
each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair and Dawn Bir resigned from his or her respective positions as a member of the Company’s board of directors
each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair and Dawn Bir resigned from his or her respective positions as a member of the Company’s board of directors
each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer
each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair and Dawn Bir resigned from his or her respective positions as a member of the Company’s board of directors
each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer
the officers of the Company are as follows: Darin M. Lippoldt (President and Secretary) and Matthew C. Abernethy (Treasurer and Vice President).
each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair and Dawn Bir resigned from his or her respective positions as a member of the Company’s board of directors
each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer
each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer
the officers of the Company are as follows: Darin M. Lippoldt (President and Secretary) and Matthew C. Abernethy (Treasurer and Vice President).
Immediately following the Effective Time, Matthew C. Abernethy and Darin M. Lippoldt became the directors of the Company
each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer
each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer
each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair and Dawn Bir resigned from his or her respective positions as a member of the Company’s board of directors
each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer
Immediately following the Effective Time, Matthew C. Abernethy and Darin M. Lippoldt became the directors of the Company
each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair and Dawn Bir resigned from his or her respective positions as a member of the Company’s board of directors
On May 18, 2026, Xponential Fitness, Inc. (the “Company”), issued a press release (the “Press Release”), announcing the appointment of Danielle Porto Parra as its President, effective as of May 18, 2026.
appointed Eugene Davis and John T. Young, Jr. to the Board
appointed Eugene Davis and John T. Young, Jr. to the Board
On May 14, 2026, the Board of Directors (the “Board”) of Kyverna Therapeutics, Inc. (the “Company”) appointed Gregory Martini as the Company’s Chief Financial Officer, effective May 18, 2026 (the “Effective Date”).
Armando Pimentel, Jr., Chief Executive Officer of Florida Power & Light Company (FPL) and a named executive officer of NextEra Energy, Inc. (NEE), resigned from such position effective May 18, 2026 and was appointed Vice Chairman of NEE effective May 18, 2026.
On July 31, 2026 (the “Effective Date”), Nicola Rossi, Chief Accounting Officer of Wyndham Hotels & Resorts, Inc. (the “Company”), will depart from the Company.
As of the Effective Date, Christopher Androski, age 52, who is currently the Company’s Senior Vice President and Controller, will assume the role of Chief Accounting Officer.
Effective May 12, 2026, each of Jan Stern Reed and Timothy Wicks were appointed to the Board of Directors of the Company
Effective May 12, 2026, each of Jan Stern Reed and Timothy Wicks were appointed to the Board of Directors of the Company
On May 13, 2026, the Board of Directors (the “Board”) of the Company, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Ivona Smith to the Board, effective May 13, 2026.
On May 14, 2026, Scott S. Prince, a director on the Board of Directors (the “Board”) of Apollo Commercial Real Estate Finance, Inc. (the “Company”), informed the Company that he will not be standing for re-election to the Board at the Company’s next annual meeting of stockholders.
On April 27, 2026, Planet 13 Holdings Inc. (the "Company") entered into a separation agreement with the Company’s former Chief Administrative Officer, Lee Fraser (the "Separation Agreement").
On May 12, 2026, in connection with his previously disclosed retirement on May 1, 2026, Ventas, Inc. (the “Company”) entered into a separation and release agreement with Peter J. Bulgarelli, Executive Vice President, Outpatient Medical & Research, Ventas, Inc. and President and CEO, Lillibridge Healthcare Services, Inc.
On May 11, 2026, Mr. David C. Frydenlund, previously Executive Vice President and Chief Legal Officer of Energy Fuels Inc. (the "Company"), transitioned into the role of Executive Vice President, Strategic Acquisitions and Financings and Special Counsel to the Chief Executive Officer, in connection with Mr. Frydenlund's planned retirement in October 2026
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.